The Patent Finder

Excalibur Pharmaceuticals, Inc.

15 patents currently held · Updated Nov 17, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Aug 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 13 to 20, 2027 · next Feb 13
  • 1 fee due Mar 26, 2027
    The maintenance fee for Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne (US 11,766,426) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
  • 1 fee due Apr 10, 2027
    The maintenance fee for Gel containing pirfenidone (US 11,779,574) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,376,500Gel containing pirfenidone
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,667,561Gel Containing Pirfenidone
In force
 · Low confidence
In forceLow confidence
US 11,779,574Gel containing pirfenidone
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,083,719Gel containing Pirfenidone
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,492,412Gel containing pirfenidone
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,962,374Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,383,862Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,040,030Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,408,836Pharmaceutical composition containing pirfenidone in sustained-release tablet form
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,949,959Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents
Also on record, not counted in the 15: 3 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 1 abandoned · 4 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited